Advertisement
Advertisement
U.S. markets open in 6 hours 28 minutes
Advertisement
Advertisement
Advertisement
Advertisement

Cogent Biosciences, Inc. (COGT)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
12.15-0.35 (-2.80%)
At close: 04:00PM EST
12.00 -0.15 (-1.23%)
After hours: 04:08PM EST
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Triple Moving Average Crossover

Triple Moving Average Crossover

Previous Close12.50
Open12.43
Bid0.00 x 800
Ask0.00 x 800
Day's Range11.85 - 12.60
52 Week Range3.79 - 18.07
Volume910,741
Avg. Volume807,556
Market Cap849.205M
Beta (5Y Monthly)-0.71
PE Ratio (TTM)N/A
EPS (TTM)-2.21
Earnings DateNov 14, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est21.17
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for COGT

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Cogent Biosciences, Inc.
    Analyst Report: Gilead Sciences, Inc.Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
    Rating
    Fair Value
    Economic Moat
    6 days agoMorningstar
View more
  • GlobeNewswire

    Cogent Biosciences to Host Investor Webcast to Discuss Updated Clinical Data at ASH from the Ongoing Phase 2 APEX Trial of Bezuclastinib in Patients with Advanced Systemic Mastocytosis

    WALTHAM, Mass. and BOULDER, Colo., Dec. 05, 2022 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced the details of its investor webcast being held on Monday, December 12, 2022 at 8:00 a.m. ET (7:00 a.m. CT) to discuss updated clinical data from its on-going Phase 2 APEX trial evaluating bezuclastinib in patients with Advanced Systemic Mastocytosis being presented at the 6

  • GlobeNewswire

    Cogent Biosciences Appoints Rachael Easton, MD, Ph.D., VP, Head of Clinical Development

    WALTHAM, Mass. and BOULDER, Colo., Nov. 28, 2022 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced the appointment of Rachael Easton, MD, Ph.D., Vice President, Head of Clinical Development. "We are pleased to welcome Dr. Easton to Cogent as we continue to develop bezuclastinib in Systemic Mastocytosis and GIST,” said Andrew Robbins, the company’s President and Chief Exe

  • GlobeNewswire

    Cogent Biosciences Reports Recent Business Highlights and Third Quarter 2022 Financial Results

    Phase 3 PEAK trial initiated comparing bezuclastinib + sunitinib vs. sunitinib alone in second line gastrointestinal stromal tumor (GIST) patients; initial safety and pharmacokinetic data from lead-in phase to be presented at CTOS 2022 Phase 2 APEX trial in Advanced Systemic Mastocytosis (AdvSM); oral presentation at ASH 2022 including assessment of patient response Developed an optimized formulation of bezuclastinib with new dosage strength and over 40% improvement in clinical exposure; potenti

Advertisement
Advertisement